DeepMed Research

Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients

Completed

Conditions: HIV Infection

Interventions: Drug: Efavirenz

First Posted Date: 2013-06-25

Last Posted Date: 2023-12-12

Lead Sponsor: University of Nebraska

Target Recruit Count: 30

Registration Number: NCT01886404

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.

Phase 1

Completed

Conditions: Solid Tumors
Non-Hodgkin's Lymphoma

Interventions: Drug: Efavirenz 600mg
Drug: Efavirenz 1200 mg
Drug: Efavirenz 1800 mg
Drug: Efavirenz 2200 mg

First Posted Date: 2013-06-17

Last Posted Date: 2021-01-27

Lead Sponsor: Institut Bergonié

Target Recruit Count: 25

Registration Number: NCT01878890

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Atripla or Stribild

First Posted Date: 2013-03-21

Last Posted Date: 2022-09-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 225

Registration Number: NCT01815580

Locations: 🇵🇪
Asociación Civil Impacta Salud y Educación, Lima, Peru

Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB

Phase 3

Completed

Conditions: HIV/TB Co-infection

Interventions: Drug: Nevirapine
Drug: Efavirenz

First Posted Date: 2013-03-06

Last Posted Date: 2013-03-26

Lead Sponsor: All India Institute of Medical Sciences, New Delhi

Target Recruit Count: 135

Registration Number: NCT01805258

Locations: 🇮🇳
All India Institute of Medical Sciences, New Delhi, India

A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

Phase 2

Completed

Conditions: HIV
Contraception

Interventions: Drug: Levonorgestrel
Drug: Nevirapine
Drug: Efavirenz

First Posted Date: 2013-02-12

Last Posted Date: 2023-09-01

Lead Sponsor: University of Nebraska

Target Recruit Count: 60

Registration Number: NCT01789879

Locations: 🇺🇬
Infectious Diseases Institute, Kampala, Uganda

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Phase 4

Completed

Conditions: HIV

Interventions: Drug: ATRIPLA

First Posted Date: 2013-01-29

Last Posted Date: 2015-09-02

Lead Sponsor: Anna Cruceta

Target Recruit Count: 60

Registration Number: NCT01778413

Locations: 🇪🇸
Hospital Clinic i Provincial Barcelona, Barcelona, Spain

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

Phase 3

Completed

Conditions: Human Immunodeficiency Virus-type 1 Infection

Interventions: Drug: Rilpivirine
Drug: Efavirenz
Drug: Tenofovir disoproxil fumarate
Drug: Emtricitabine

First Posted Date: 2012-10-17

Last Posted Date: 2021-02-11

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 426

Registration Number: NCT01709084

Efavirenz Comparative Bioavailability

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Efavirenz 600 Test-Stocrin 600 Reference
Drug: Stocrin 600 Reference-Efavirenz 600 Test

First Posted Date: 2012-10-12

Last Posted Date: 2013-08-14

Lead Sponsor: Center for Clinical Pharmacology Research Bdbeq S.A.

Target Recruit Count: 12

Registration Number: NCT01704898

Locations: 🇺🇾
Center for Cllinical Pharmacology Research-Bdbeq S.A., Montevideo, Uruguay

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Phase 1

Completed

Conditions: HIV
Hyperlipidemia

Interventions: Drug: Pitavastatin
Drug: Efavirenz
Drug: Darunavir
Drug: Ritonavir

First Posted Date: 2012-09-28

Last Posted Date: 2020-08-11

Lead Sponsor: NYU Langone Health

Target Recruit Count: 34

Registration Number: NCT01695954

Locations: 🇺🇸
Bellevue/NYU AIDS Clinical Trials Unit, New York, New York, United States

Efavirenz and Ritonavir on Human Brain P-Glycoprotein

Phase 1

Completed

Conditions: Drug Effects

Interventions: Drug: [11C] desmethyl-loperamide
Other: Control - no pretreatment
Drug: Oral ritonavir
Drug: Oral efavirenz

First Posted Date: 2012-08-17

Last Posted Date: 2020-01-22

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 13

Registration Number: NCT01668147

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy